Abstract Body

With the goal of ending the HIV epidemic in the United States, access to HIV Pre-exposure Prophylaxis (PrEP) is essential to curb new HIV infections. There has been differential regional uptake of PrEP with the South lagging behind. We explore a potential systemic barrier: prior authorization (PA) requirements. This study explores differential PA for PrEP across geography and insurance characteristics.

The design was a cross-sectional study of all individual Qualified Health Plans (QHPs) offered in the 2019 Affordable Care Act Marketplace. QHP PA requirement for combined tenofovir disoproxil fumarate and emtricitabine (PrEP) was our primary outcome. Log binomial regression was used to estimate the association between region and PA requirement, and assess whether other plan characteristics (national issuer, high deductible, PrEP cost sharing structure, PrEP specialty drug tier status, plan level, rating area urbanicity, and rating area competition) may explain regional disparities in PA.

16,853 QHPs were analyzed (18% Northeast, 20% West, 25% Midwest, and 37% South). Overall, 19% of plans required PA for PrEP. Compared to plans in the Northeast, a plan in the South was 15.9 (95% Confidence Interval (95% CI), 12.6-20.1) times as likely to require PA whereas the Midwest and West were 5.7 (95% CI, 4.5-7.3) and 2.7 (95% CI, 2.0-3.5) times as likely, respectively. Figure 1 demonstrates QHPs' PA rate for PrEP by rating area. National issuers were more common in the South (Risk Ratio [RR] 1.9, 95% CI, 1.7-2.2) and were more likely to require PAs (RR 3.3, 95% CI, 3.1-3.6). This may mediate part of the high PA rate in the South, but it does not completely explain the disparity. QHP factors that shift drug costs to consumer, such as co-insurance cost sharing, specialty drug tiering, catastrophic level plans, were associated with lower likelihood of PA, but these characteristics were unlikely to explain regional disparities.

QHPs in the South are 16 times as likely to require PrEP PA. PA reduces the chance of obtaining a prescribed medication. High PA rates are a possible barrier to PrEP access in the South, which is the region with the most new HIV diagnoses. Due to PrEP’s USPSTF Grade A rating, QHPs must start offering PrEP without cost-sharing starting in 2021. However, there is no regulation on QHPs’ use of PA for PrEP. We have the tools to end the HIV epidemic, and we will also need robust health policies to end the HIV epidemic.